HC Wainwright Reiterates Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 140.96% from the company’s current price.

Several other research analysts also recently commented on the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Celldex Therapeutics in a report on Wednesday. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $63.83.

Celldex Therapeutics Stock Up 1.0 %

Shares of CLDX stock opened at $33.20 on Thursday. The company has a 50 day moving average of $38.42 and a 200-day moving average of $38.43. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market cap of $2.20 billion, a P/E ratio of -11.61 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. As a group, equities analysts expect that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after buying an additional 427,827 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after buying an additional 1,413,722 shares in the last quarter. Affinity Asset Advisors LLC raised its position in shares of Celldex Therapeutics by 166.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after buying an additional 250,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after buying an additional 2,664,915 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock valued at $4,797,000 after buying an additional 17,300 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.